Axsome Therapeutics Hosts AUVELITY FDA Approval Investor Event Featuring Expert Thought Leader

Image for article Axsome Therapeutics Hosts AUVELITY FDA Approval Investor Event Featuring Expert Thought Leader
News Source : Financial Post

News Summary

  • AUVELITY (dextromethorphan HBr/bupropion HCl) is an oral N-methyl-D-aspartate (NMDA) receptor antagonist, sigma-1 agonist, and aminoketone CYP2D6 inhibitor.
  • AUVELITY is a first-in-class medicine, with a distinct mechanism of action, for the treatment of agitation associated with dementia due to Alzheimer’s disease.
  • It is a prescription medicine used to treat adults with major depressive disorder (MDD)
Review the list below with your HCP. AUVELITY may not be right for you ifFor more information about AUVELITY, call 8664962976 or visit AUVELITY.com.This summary provides basic information abou [+5381 chars]

Must read Articles